Patent 11,786,487 (US) claim scope and US patent landscape for fenfluramine + stiripentol (seizure reduction via reduced norfenfluramine)
United States Patent 11,786,487 is a method-of-treatment patent with a pharmacokinetic mechanism as the claim anchor. Claim 1 recites administering liquid fenfluramine (or salt) plus stiripentol to reduce formation of norfenfluramine, increasing fenfluramine exposure, thereby reducing or ameliorating seizures. Dependent claims narrow to specific refractory epilepsy syndromes (Dravet, Lennox-Gastaut, Doose, West) and allow extensive co-therapy lists, with Claim 7 further narrowing to pediatric dosing ranges for both actives using liquid formulations. The estate’s practical moat, as written, is the combination regimen (fenfluramine liquid + stiripentol liquid) and the specific PK effect on norfenfluramine, plus syndrome and dose-range constraints in narrower claims.
What does US Drug Patent 11,786,487 claim, and what is the enforceable scope?
Core claim construction (Claim 1):
- Condition/endpoint: “method of reducing or ameliorating seizures in a patient”
- Act 1: administer a therapeutically effective amount of liquid formulation of fenfluramine (or pharmaceutically acceptable salt)
- Act 2: administer therapeutically effective amount of stiripentol
- Mechanism/functional limitation: “thereby modulating down formation of norfenfluramine and resulting in higher levels of fenfluramine.”
What is broad vs narrow:
- Broad: no syndrome requirement in Claim 1; no explicit dose mg/kg; no explicit schedule or co-therapy requirement.
- Narrower: requires liquid fenfluramine formulation and a regimen that achieves (by functional linkage) reduction of norfenfluramine formation with concomitant increased fenfluramine levels.
How the “norfenfluramine modulation” functions legally in scope:
- The “thereby” clause ties the combination to a measurable biochemical outcome (less norfenfluramine, higher fenfluramine). In practice, this can be used as:
- a limitation to avoid prior art with different metabolism or without stiripentol,
- a proof element (pharmacodynamic/PK evidence) for infringement.
- If an accused regimen uses fenfluramine + stiripentol but does not actually reduce norfenfluramine formation (or if the relationship is not met), infringement arguments can be framed around functional limitation.
Claim 2 and Claim 3 narrowing:
- Claim 2: patient diagnosed with Dravet syndrome
- Claim 3: patient diagnosed with refractory epilepsy selected from Dravet, Lennox-Gastaut, Doose, West
This creates a two-tier structure:
- general “refractory seizures” across syndromes in Claim 1 (by endpoint alone),
- stronger syndrome-specific coverage in dependent claims.
What dosing and formulation limitations are covered by Claim 7 and Claim 9?
Claim 7 (pediatric dosing + liquid formulation + PK effect):
- Syndrome: “refractory epilepsy selected from” Dravet, Lennox-Gastaut, Doose, West
- Act 1: administer liquid fenfluramine at 0.2 mg/kg/day to 0.8 mg/kg/day
- Act 2: administer liquid stiripentol at about 20 mg/kg/day to about 50 mg/kg/day
- Mechanism: stiripentol modulates down norfenfluramine formation resulting in higher fenfluramine levels
Claim 9 (Dravet-only plus dosing ranges):
- Repeats the same dosing ranges and liquid formulation requirements for both drugs.
- Limits the patient to Dravet syndrome.
Enforceable impact:
- The dose-range language is a material narrowing point. If an accused product or regimen sits entirely outside 0.2–0.8 mg/kg/day for fenfluramine or 20–50 mg/kg/day for stiripentol, the infringement analysis will pivot to:
- whether “range” is interpreted strictly or whether overlap can be argued,
- whether off-range regimens still fall under broader Claim 1 (if liquid + PK outcome is satisfied) or whether the plaintiff relies on dependent claims only.
Formulation is part of the claim:
- Both Claims 7 and 9 expressly require liquid formulation for fenfluramine and stiripentol.
- If an accused regimen uses a non-liquid fenfluramine presentation or a stiripentol presentation not meeting “liquid formulation,” the dependent claims may be easier to design around, while Claim 1 may still capture “liquid formulation of fenfluramine” but not necessarily a non-liquid stiripentol unless stiripentol is also provided in a qualifying liquid form for the combination regimen.
Which co-therapies are expressly allowed in the claim set, and does that expand or cabin infringement?
Claim 4 (large co-therapeutic list)
- Requires adding a co-therapeutic agent chosen from a long list (including many standard antiseizure medicines such as clobazam, valproate, topiramate, valproate salts, carbamazepine-like agents, benzodiazepines, and others).
- Claim 5 narrows to the same syndrome set (Dravet, Lennox-Gastaut, Doose, West).
Claim 6 (subset)
- Limits co-therapy to clobazam and valproate.
Why this matters for enforcement:
- These dependent claims confirm that the patent owner positioned the invention as compatible with common add-on therapy.
- For infringement strategy:
- if an accused regimen uses clobazam + valproate, Claim 6 is the cleanest target,
- if an accused regimen uses a different listed agent, Claim 4 may be the anchor.
What the lists do not do:
- The language does not automatically broaden the independent claim to include any co-therapy.
- The independent combination remains fenfluramine liquid + stiripentol; the co-therapy lists are tied to dependent claims.
How does US 11,786,487 compare with typical fenfluramine patent coverage (what is likely protected vs what is left open)?
Likely protected elements (by your claim text):
- Combination regimen: fenfluramine + stiripentol
- Formulation constraint: liquid fenfluramine (and in narrower claims, liquid stiripentol)
- PK/mechanism linkage: reduction in norfenfluramine formation with increased fenfluramine
- Use/indication constraints in dependents: specific pediatric epilepsy syndromes and refractory epilepsy framing
- Dose ranges in dependents: mg/kg/day windows
Potential gaps typical for estates like this (based on the claim text you provided):
- No explicit claims here for:
- a fixed dosing schedule (timing constraints),
- specific manufacturing or formulation composition parameters for either liquid beyond “liquid formulation,”
- method-of-administering variations (titration steps, loading dose),
- non-liquid presentations (tablets/capsules) or alternative stiripentol dosage forms.
- That means competitors could target non-liquid formulations or dose regimens outside the narrow dependent windows, while still risking independent Claim 1 if the PK outcome and “liquid fenfluramine” conditions are met.
What is the patent landscape risk for generics or competitors if they try to launch fenfluramine with stiripentol?
Risk drivers that keep this claim set relevant:
- Combination is explicitly the invention (fenfluramine liquid + stiripentol).
- Functional PK outcome is part of the claim, making it harder to argue the effect is incidental if stiripentol predictably reduces norfenfluramine formation.
- Syndrome targets align to common clinical practice areas where stiripentol is already used.
Where generic/competitor risk concentrates:
- If an ANDA/505(b)(2) pathway results in a marketed product regimen that matches:
- liquid fenfluramine,
- therapeutically effective stiripentol dosing,
- achieved norfenfluramine suppression with higher fenfluramine exposure,
then Claim 1 exposure remains.
Where design-around leverage exists:
- Avoid “liquid formulation” of fenfluramine.
- Avoid “liquid formulation” of stiripentol (to try to escape dependent claims 7/9).
- Dose outside the dependent claims’ specified windows.
- Use co-therapy combinations that do not include listed agents will not avoid Claim 1, but can matter for dependent-claim infringement targeting.
What patent estate arguments tend to arise around “modulating norfenfluramine” mechanism?
Because Claim 1 includes a “thereby” PK-mechanism limitation, disputes typically focus on:
- Whether stiripentol reduces norfenfluramine formation in the accused regimen at clinically relevant levels.
- Whether the “resulting in higher levels of fenfluramine” is shown or required as a matter of claim construction vs a contingent outcome.
From a litigation perspective, this mechanism language is both:
- a feature (distinguishing over prior art combinations that do not produce that PK effect), and
- a burden (plaintiff must connect the combination to norfenfluramine suppression and fenfluramine increase).
In practical enforcement, the mechanism typically invites:
- plasma level comparisons,
- metabolite quantification (norfenfluramine),
- and PK modeling tied to dose and formulation.
What Orange Book status questions affect this patent’s enforcement?
No Orange Book listing or FDA-application linkage is provided in the prompt content. Without application numbers, listed drug identifiers, or specific Orange Book patents in force for the relevant fenfluramine NDA/505(b)(2), the enforceability map by listed-drug/claim is not derivable from the claim text alone.
Key takeaways
- US 11,786,487 protects a combination method: liquid fenfluramine + stiripentol to reduce norfenfluramine formation and thereby increase fenfluramine exposure to reduce seizures.
- The broadest coverage is Claim 1 (no syndrome requirement; no explicit dose ranges; but liquid fenfluramine and the PK mechanism are claim limitations).
- Claims 7 and 9 add enforceable tight points: pediatric mg/kg/day ranges and liquid stiripentol plus syndrome targeting (refractory epilepsy set for claim 7; Dravet-only for claim 9).
- Co-therapy lists (Claims 4 and 6) reinforce that the regimen is intended for real-world add-on antiseizure therapy, with the tightest dependent coverage for clobazam + valproate.
- Competitive risk for fenfluramine + stiripentol regimens is highest when the marketed regimen matches liquid formulation requirements and is consistent with the norfenfluramine suppression / fenfluramine increase PK mechanism.
FAQs
1) Does US 11,786,487 require a specific dosing schedule or only dose range?
The independent claim uses “therapeutically effective amount,” while the narrowest dependents specify fenfluramine and stiripentol mg/kg/day ranges.
2) Is the mechanism (norfenfluramine suppression) a result or a limitation?
In the claim text, it is a functional limitation tied to the administering steps (“thereby modulating down formation of norfenfluramine”).
3) Can an accused regimen avoid infringement by changing co-therapeutic antiseizure drugs?
Changing co-therapy may avoid dependent-claim coverage (Claims 4/6) but does not avoid Claim 1 unless the regimen also escapes the liquid formulation and PK mechanism limitations.
4) What is the strictest point of claim coverage for pediatric patients?
Claims 7 and 9: the combination of (i) syndrome restriction, (ii) liquid formulations for both drugs, and (iii) the specified 0.2–0.8 mg/kg/day fenfluramine and 20–50 mg/kg/day stiripentol ranges.
5) If a competitor uses non-liquid fenfluramine, is the patent still implicated?
The dependents explicitly require liquid formulation for both drugs, and Claim 1 requires liquid fenfluramine; a non-liquid presentation is a direct way to avoid at least the liquid limitation.
References
- United States Patent 11,786,487 (claims as provided in prompt).
